报价延迟最少15分钟:2026/05/30 07:06 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.46 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.28/-4.23
|
|
企业价值
56.58M
|
| 资产负债 |
|
每股账面净值
12.13
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
43.77M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Itsintegrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases. |
